possible cr options, page-5

Steini,
We need to wait for the details of the CR.
As you mentioned, it might be partly or entirely taken up by an insto at a negotiated price, can be all part of the DD.


No use in speculating about conditions we do not know yet.


Regarding lengthy due diligence period prior to this TH, I would suspect to see a cornerstone investor involved.
To what extend, we will see maybe tomorrow.
That would also explain why we did not raise earlier.


There is simply no reason to assume that pharmas do not show interest in ATL1103. ISIS made a direct reference to the great interest in rare disease treatment and mentioned ATL1103 directly in its presentation to investors.